PIK3CA and colorectal carcinoma: Another compensatory effect of alternative pathway activation, such as PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) mutation, may contribute to the constitutive activation of downstream pathways in patients with CRC with acquired anti-EGFR resistance [111].